Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.61 |
| ▸ | CTSK | P43235 | 13/20 | 0.61 |
| ▸ | CTSB | P07858 | 4/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.61 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781555 | 1.00 | CTSS (0.61) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL19236869 | 1.00 | CTSS (0.61) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL28803148 | 1.00 | CTSS (0.61) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL19236710 | 0.88 | CFD (0.52) | CTSSCTSKCTSBCTSLCYP3A4 | |
| SCHEMBL30146876 | 0.88 | CFD (0.52) | CTSSCTSKCTSBCTSLCYP3A4 | |
| SCHEMBL19236696 | 0.87 | CTSS (0.48) | CTSSCTSKCTSBCTSLCYP3A4 | |
| SCHEMBL28803175 | 0.87 | CTSS (0.48) | CTSSCTSKCTSBCTSLCYP3A4 | |
| SCHEMBL29781803 | 0.87 | CTSS (0.48) | CTSSCTSKCTSBCTSLCYP3A4 | |
| SCHEMBL19236859 | 0.86 | CTSS (0.51) | CTSSCTSKCTSBCTSL | |
| SCHEMBL30146896 | 0.86 | CTSS (0.51) | CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |